See the DrugPatentWatch profile for Tivicay
Tivicay, an HIV integrase inhibitor, is currently protected by several patents. The primary patent covering the drug, U.S. Patent No. 8,173,663, is set to expire in December 2027 [1]. However, patent expiration dates can be complex, often involving multiple patents with varying expiration timelines and the potential for extensions or legal challenges [2].
When does Tivicay's U.S. market exclusivity end?
The main U.S. patent for Tivicay (dolutegravir), U.S. Patent No. 8,173,663, is scheduled to expire on December 15, 2027 [1]. This date signifies a key point for potential generic competition.
Can generic versions of Tivicay be produced before patent expiration?
Generally, generic versions of a drug cannot be manufactured or marketed in the U.S. until the relevant patents expire and any market exclusivities have concluded. However, the landscape of drug patents is intricate. Companies often file Paragraph IV certifications to challenge existing patents, which can lead to earlier generic entry if successful [2]. DrugPatentWatch.com tracks these patent statuses and potential challenges [1].
What other patents protect Tivicay?
In addition to U.S. Patent No. 8,173,663, Tivicay is protected by other patents, including those related to its formulation and method of use. These secondary patents may have different expiration dates, potentially extending market protection beyond the primary patent's expiry [1, 2].
How might patent expiry affect Tivicay's price?
Upon patent expiration and the subsequent entry of generic Tivicay, prices are typically expected to decrease significantly due to increased competition. Generic drugs are generally more affordable than their brand-name counterparts [3].
Who manufactures Tivicay?
Tivicay is manufactured by ViiV Healthcare [4]. ViiV Healthcare is an independent, global specialist HIV company owned by Pfizer, Shionogi, and GSK [4].
What are the implications of Tivicay's patent expiry for HIV treatment?
The expiration of Tivicay's patents will likely open the door for more affordable generic options for patients treating HIV. This increased access to cost-effective treatments is a critical step in global HIV management [3].
How does Tivicay work, and what is it used for?
Tivicay (dolutegravir) is an integrase strand transfer inhibitor (INSTI) medication used to treat human immunodeficiency virus (HIV) infection [5]. It works by blocking the integrase enzyme, which HIV needs to replicate [5]. It is often used in combination with other HIV medications [5].
Sources:
1. "Tivicay Patent Expiration." DrugPatentWatch.com.
2. "Drug Patent Expiration & Generic Entry." DrugPatentWatch.com.
3. "Generic Drug Approvals & Pricing." Food and Drug Administration.
4. "About ViiV Healthcare." ViiV Healthcare.
5. "Tivicay Prescribing Information." ViiV Healthcare.